### **PH** ADVICE

### **COMMENTARY ON DISEASE SURVEILLANCE SUMMARIES**

It's pleasing to note that campylobacter rates this summer have been lower than in recent years.

We were surprised to have 5 notifications for meningococcal disease in the first two weeks of January, 3 were eventually laboratory confirmed and all were the epidemic strain, the other two were not laboratory confirmed. Two cases were in a small community and had some contacts in common, meeting the definition of an outbreak. We will continue to monitor this situation and consider appropriate additional interventions should there be further cases in that community.

### **IMMUNISATION ISSUES**

## **Childhood Immunisation Schedule Changes**

The next national schedule change will take place this year, with implementation of the pneumococcal programme planned from 1 June 2008. Key schedule changes are as follows:

## Prevenar: Pneumococcal conjugate vaccine

- Available from 1 June 2008
- •Given to all infants at 6 weeks, 3 months, 5 months and 15 months
- •Catch up will be available for all infants born from 1 January 2008 (these infants will be offered a course of three doses with each dose 6 weeks apart, and a booster dose when they turn 15 months old)

### Infanrix-Hexa:hexavalent vaccine

- •DTaP-HepB/Hib will be available from 1 March 2008
- •This is a single dose vaccine to replace the two vaccines currently given at 6 weeks, 3 months, 5 months.

# Boostrix-dTap vaccine

The polio dose for 11 year olds will be removed from January 2008:
dTap (diptheria, tetanus, acellular pertussis adult dose-Boostrix) will continue on the schedule.

# High-risk pneumococcal programme

•Expansion of eligibility criteria for programme (criteria still to be confirmed)

The conjugate vaccine being introduced- Prevenar- is highly effective in infants, with efficacy around 88% against vaccine serotypes for invasive disease, with a 22% reduction in radiological confirmed pneumonia and a 6% reduction in otis media rates. Note that Prevenar only covers seven serotypes but these seven types cover approximately 80% of all serotypes for children under 5 years.



Inside

- Antenatal HIV Screening Project
- Immunisation Issues

Public Health Report


March 2008

Vol. 5, Issue 1

#### **IMMUNISATION COVERAGE RATES**

The first Hawkes Bay children that were registered on NIR from 12 September 2005 onwards have now reached 2 years and coverage rates for the first quarter are available.

http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-coverage-data



Immunisation Coverage for Children who have reached the milestone ages of 6 months, 12 months, 18 months, 24 months and fully completed their age appropriate immunisations for the 12 month period 01/01/2007 - 01/01/2008

These figures show that 80% of Hawkes Bay babies are fully vaccinated at 2 years of age (75% of Maori children).

Thank you for the effort that is going in to improve these rates which are continuing to rise. In particular we would like to acknowledge the success of the Wairoa practices. Wairoa PHO had 90% of babies fully vaccinated by the age of 2 years (91% of Maori babies) - a wonderful result and a great example of how it is possible to achieve high immunisation rates even in areas of high deprivation with a large Maori population.

Marg Dalton Immunisation Team

Public Health: Phone (06) 834 1815

Website: www.healthinhawkesbay.co.nz





### **ANTENATAL HIV SCREENING PROJECT**

The Universal Offer for Antenatal HIV Screening for pregnant women will be implemented in Hawkes Bay from July 1 2008. This screening programme aims to minimise the incidence of mother to child transmission and to enable early treatment of HIV positive women. While the incidence of HIV in New Zealand is low, the overall number of new infections is rising, particularly for women. Between 2002 and 2005 eight children were born HIV positive to mothers who had undiagnosed HIV infection during pregnancy. Over the same period no children were born HIV positive where mothers were identified during pregnancy.

Work is in progress to develop standardised test requests from Lead Maternity Carers and GPs to the laboratories, and resources to guide practitioners in the national testing and result confirmation algorithms.

A Programme Coordinator will be appointed to provide practitioner training, and to support practitioners after the implementation. Details of training and the availability of the National Guidelines will be publicised once details are confirmed.


For further information contact Chris Styles, Project Manager, Public Health Unit, Napier Health Centre, phone 06 834 1815.

Chris Styles Project Manager

# CONTACTS OF NOTIFIABLE DISEASE

From time to time, particularly with the higher profile notifiable disease like Meningococcal Disease or Tuberculosis, GPs and ED staff will be consulted by contacts of cases seeking advice, investigation, or treatment. Sometimes public health staff doing the investigation will already have contacted them and provided advice or organised to meet them to provide prophylaxis but the contacts feel more urgent prophylaxis is required. If you see people in this situation, please check with the public health unit first (or the on call Health Protection Officer after hours). This will enable us to gather more information and/or widen our list of contacts, to ensure consistency of information and intervention, and to ensure compliance with protocols/guidelines in terms of how different categories of contacts are managed.

### **DISEASE SURVEILLANCE SUMMARIES**



| Disease               | Hawke's Bay |       | New Zealand |      |
|-----------------------|-------------|-------|-------------|------|
|                       | Cases       | rate* | Cases       | rate |
| Campylobacter         | 416         | 281.7 | 10590       | 250. |
| Cryptosporidium       | 33          | 22.3  | 873         | 20.  |
| Gastroenteritis       | 19          | 12.9  | 612         | 14.  |
| Giardia               | 37          | 25.1  | 1409        | 33.  |
| Hepatitis A           | 3           | 2.0   | 42          | 1.   |
| Hepatitis B           | 4           | 2.7   | 68          | 1.   |
| Lead Absorption       | 2           | 1.4   | 87          | 2.   |
| Leptospirosis         | 12          | 8.1   | 61          | 1.   |
| Meningococcal disease | 14          | 9.5   | 108         | 2.   |
| Paratyphoid           | 1           | 0.7   | 27          | 0.   |
| Pertussis             | 8           | 5.4   | 289         | 6.   |
| Rheumatic fever       | 8           | 5.4   | 212         | 5.   |
| Salmonellosis         | 50          | 33.9  | 1427        | 33   |
| Shigellosis           | 2           | 1.4   | 121         | 2    |
| Tuberculosis          | 16          | 10.8  | 302         | 7.   |
| VTEC/STEC Infection   | 2           | 1.4   | 119         | 2    |
| Yersinia              | 33          | 22.3  | 555         | 13   |

<sup>\*</sup> Annualised crude rate per 100,000 population calculated from 2006 census usually resident population.

Public Health: Phone (06) 834 1815

Website: www.healthinhawkesbay.co.nz

